ICARE Newsletter Winter 2021

Updates to National Comprehensive Cancer Network (NCCN) Guidelines Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Released September 8th, 2020:

Genetic testing criteria by cancer type:

Breast Cancer:

  • Broadened to include relatives with ALL grades of prostate cancer (not just high-grade)
  • Having multiple breast cancer diagnoses no longer depends on whether the diagnoses were on two different breasts

Prostate Cancer:

  • Now includes cribriform histology and ANY risk group (not just high-grade prostate cancer)
  • Only first-degree relatives should be offered genetic testing

Pancreatic Cancer:

  • Only first-degree relatives should be offered genetic testing


Released September 8th, 2020:

Breast cancer risk management recommendations by gene:

  • NBN: high-risk breast screening was removed as there is insufficient evidence to support high breast cancer risks
  • BARD1: added consideration for high-risk breast screening starting at age 40
  • RAD51C & RAD51D: risks for triple-negative breast cancer were broadened to include potential increase in female breast cancer risk
  • BRCA1/2: in men with gynecomastia, added consideration for annual mammogram at age 50 (or 10 years before earliest male breast cancer diagnosis in the family)


Released November 20th, 2020:
Inherited cancer gene tables expanded to include more detailed risk information, level of risk, and strength of evidence

Check out the full NCCN guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/1nlw2021/